MUNICH — Long-term oral anticoagulation (OAC) with rivaroxaban (Xarelto, Bayer/Janssen Pharmaceuticals) had no apparent effect on risk for death, myocardial infarction (MI), or stroke in a large ...
CHICAGO, IL—Low-dose rivaroxaban reduces thromboembolic events in patients with worsening heart failure, reduced ejection fraction, CAD, and normal sinus rhythm, a post hoc analysis of the COMMANDER ...
ATHENS, Greece—Investigators digging deeper into the stroke results from COMMANDER HF have found that low-dose rivaroxaban (Xarelto; Bayer/Janssen) appears to “markedly reduce” the risk of stroke and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results